20/20 BioLabs, Inc. (Nasdaq: AIDX) announced its financial results for the year ended December 31, 2025, reporting a revenue of $2.0 million, which reflects a 17% increase from the previous year. The company also highlighted a significant improvement in gross profit, which surged by 68% to $0.6 million, resulting in a gross margin expansion of 900 basis points to 29.6%. This growth is attributed to the successful performance of its OneTest and CLIAx revenue streams. The company has also reduced its total operating expenses by 35%, bringing them down to $3.9 million from $6.0 million in FY 2024. Despite the improvements, the net loss for FY 2025 was $3.7 million, a 33% reduction compared to the $5.6 million loss in FY 2024. Looking ahead, 20/20 BioLabs is optimistic about its growth trajectory, particularly with the launch of its OneTest for Longevity and the recent $520,000 funding from the Maryland Department of Health for cancer screenings. The company is also set to benefit from the Medicare Multi-Cancer Early Detection Screening Act, which could enhance its revenue potential in the coming years. CEO Jonathan Cohen expressed confidence in the company's strategic direction and operational discipline, positioning 20/20 BioLabs for substantial growth in 2026.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.